Free Trial
OTCMKTS:VYNT

Vyant Bio (VYNT) Stock Price, News & Analysis

Vyant Bio logo
$0.19 +0.01 (+7.78%)
As of 12/29/2023

About Vyant Bio Stock (OTCMKTS:VYNT)

Key Stats

Today's Range
$0.18
$0.20
50-Day Range
$0.19
$0.19
52-Week Range
$0.14
$1.58
Volume
19,100 shs
Average Volume
161,822 shs
Market Capitalization
$1.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Stock News Headlines

Vyant Bio Inc VYNT
The one deadline Elon can't afford to miss...
For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for it: "Elon Time." But this time... it’s different. A fleet of autonomous robotaxis is scheduled to be unleashed on the streets of Austin, Texas, this June.
Vyant Bio Provides Update on Winddown Activities
See More Headlines

VYNT Stock Analysis - Frequently Asked Questions

Vyant Bio's stock was trading at $0.1940 on January 1st, 2025. Since then, VYNT stock has increased by 0.0% and is now trading at $0.1940.
View the best growth stocks for 2025 here
.

Vyant Bio, Inc. (OTCMKTS:VYNT) issued its earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.75). The company earned $1.51 million during the quarter, compared to analyst estimates of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%.
Read the conference call transcript
.

Vyant Bio's stock reverse split before market open on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vyant Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/11/2021
Today
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
OTCMKTS:VYNT
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,690,000.00
Net Margins
-3,474.81%
Pretax Margin
-3,281.86%

Debt

Sales & Book Value

Annual Sales
$670,000.00
Price / Cash Flow
N/A
Book Value
$1.69 per share
Price / Book
0.11

Miscellaneous

Free Float
5,724,000
Market Cap
$1.23 million
Optionable
Not Optionable
Beta
1.73
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (OTCMKTS:VYNT) was last updated on 5/12/2025 by MarketBeat.com Staff
From Our Partners